» Articles » PMID: 16613343

Coexistent Anaplastic and Differentiated Thyroid Carcinoma: an Immunohistochemical Study

Overview
Specialty Pathology
Date 2006 Apr 15
PMID 16613343
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to clarify the underlying molecules that might contribute to the highly aggressive behavior of anaplastic thyroid carcinoma. We selected 5 cases of anaplastic thyroid carcinoma that had a differentiated area to determine differences in the molecules of undifferentiated and differentiated cancer cells. We immunohistochemically examined the localization of nuclear antigen (Ki-67), proliferating cell nuclear antigen (PCNA), p53, apoptotic protease-activating factor-1 (Apaf-1), CD26, galectin-3, E-cadherin, and CD147. We found increased Ki-67, PCNA, and p53 labeling indices; decreased levels of Apaf-1, CD26, galectin-3, and E-cadherin; and overexpression of CD147 in the undifferentiated area compared with the differentiated area. These findings indicate high proliferative properties, suppression of apoptosis, disruption of cell-cell interaction, and induction of matrix metalloproteinases in the undifferentiated areas. Thus the molecules examined might be useful for evaluating the aggressive nature of this tumor and the prognosis.

Citing Articles

Immunohistochemical basigin expression level in thyroid cancer tissues.

Guo W, Tang D, Pang Y, Li X, Chen G, Huang Z World J Surg Oncol. 2020; 18(1):240.

PMID: 32891152 PMC: 7487720. DOI: 10.1186/s12957-020-01975-9.


Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review).

Gao Y, Li B, Wu X, Cui J, Han J Oncol Rep. 2014; 31(3):1035-42.

PMID: 24424445 PMC: 3926673. DOI: 10.3892/or.2014.2978.


Stem cells and cancer stem-like cells in endocrine tissues.

Lloyd R, Hardin H, Montemayor-Garcia C, Rotondo F, Syro L, Horvath E Endocr Pathol. 2013; 24(1):1-10.

PMID: 23435637 DOI: 10.1007/s12022-013-9235-1.


CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.

Ke C, Liu R, Yang A, Liu C, Chi C, Tseng L Eur J Nucl Med Mol Imaging. 2012; 40(1):61-71.

PMID: 23081821 PMC: 3510415. DOI: 10.1007/s00259-012-2242-5.


Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush P, Asioli S Mod Pathol. 2012; 26(1):54-61.

PMID: 22899291 PMC: 3559085. DOI: 10.1038/modpathol.2012.137.